Position in NVS
as of Jun 30, 2026
· filed Jul 16, 2026
Position Value
$608,543
+$80,334 QoQ
Shares Held
3,883
+12.3% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.31%
of 13F equity value
Holder Rank
#804
of 1,603 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026RIVERSEDGE ADVISORS, LLC holds $8,081,117 across 10 Drug Manufacturers - General names. NVS ranks #6 (7.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
6,231 | $1,582,487 | |
| 2 | LLY |
ELI LILLY & Co
|
1,159 | $1,390,139 | |
| 3 | ABBV |
AbbVie Inc.
|
4,666 | $1,174,152 | |
| 4 | BMY |
Bristol Myers Squibb Co
|
19,575 | $1,127,911 | |
| 5 | MRK |
Merck & Co., Inc.
|
6,880 | $884,080 | |
| 6 | NVS |
Novartis AG
This page
|
3,883 | $608,543 | |
| 7 | AZN |
Astrazeneca PLC
|
2,280 | $432,333 | |
| 8 | BIIB |
Biogen Inc.
|
1,746 | $377,240 |
All Filings in NVS
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $608,543 | 3,883 | Shares | Sole | 2026-07-16 | |
| 2026-03-31 | $528,209 | 3,458 | Shares | Sole | 2026-04-16 | |
| 2025-12-31 | $464,759 | 3,371 | Shares | Sole | 2026-01-07 | |
| 2025-09-30 | $406,520 | 3,170 | Shares | Sole | 2025-10-09 | |
| 2025-06-30 | $335,560 | 2,773 | Shares | Sole | 2025-07-09 | |
| 2025-03-31 | $263,873 | 2,367 | Shares | Sole | 2025-05-01 | |
| No filing history on record for this holder in this stock. | ||||||